Ppd Stock News

Zacks Investment Research lowered shares of PPD (NASDAQ:PPD) from a hold rating to a sell rating in a research report sent to investors on Wednesday, Zacks.com reports. According to Zacks, PPD Inc. is a contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. It serves pharmaceutical, biotechnology, medical device, academic and []

The real world evidence solutions market is expected to witness market growth at a rate of 12.22% in the forecast period of 2021 to 2028 and is expected to reach USD 1,933.16 million by 2028. Data Bridge Market Research report

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) earned numerous honors at the 2021 PharmaTimes Clinical Researcher of the Year-The Americas competition. Two PPD teams won gold, one team won

Related Stocks: ACRS , EPIX , CRIS , BGNE , RCKT , MRTX , CPNG , PPD , KSU , CHNG , FIVN , ARNA , WLTW , MXIM , ALXN , WORK , SOGO , GRUB ,

Marshall Wace LLP raised its holdings in shares of PPD, Inc. (NASDAQ:PPD) by 56.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 338,478 shares of the companys stock after buying an additional 121,878 shares during the period. Marshall Wace LLP owned about 0.10% of []

Charles Schwab Investment Management Inc. boosted its position in shares of PPD, Inc. (NASDAQ:PPD) by 13.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 346,896 shares of the companys stock after buying an additional 39,993 shares during the period. []

PPD, Inc. (PPD) CEO David Simmons on Q3 2021 Results - Earnings Call Transcript

PPD, Inc. (PPD) delivered earnings and revenue surprises of 16.22% and 7.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021. Highli

PALO ALTO, Calif.--(BUSINESS WIRE)-- #biotech--Medable secured $304 million in Series D funding at $2.1 billion valuation to accelerate global adoption of digital and decentralized clinical trials.

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) was named “Clinical Research Company of the Year” at the 2021 PharmaTimes Clinical Researcher of the Year International competition in Lo

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Third Quarter 2021 Earnings Conference Call

PPD, Inc. (PPD) CEO David Simmons on Q2 2021 Results - Earnings Call Transcript

PPD, Inc. (PPD) delivered earnings and revenue surprises of 14.71% and 17.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PPD, Inc. (NASDAQ: PPD) to Thermo Fisher Scientific Inc. for $47.50 per share is fa